Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia

Haematologica

Volumn 97, Issue 10, 2012, Pages 1586-1593

  Gaipa, Giuseppe ^a   Cazzaniga, Giovanni ^a   Valsecchi, Maria Grazia ^a   Panzer Grümayer, Renate ^b   Buldini, Barbara ^c   Silvestri, Daniela ^a   Karawajew, Leonid ^d   Maglia, Oscar ^a   Ratei, Richard ^d   Benetello, Alessandra ^c   Sala, Simona ^a   Schumich, Angela ^b   Schrauder, Andre ^e   Villa, Tiziana ^a   Veltroni, Marinella ^f   Ludwig, Wolf Dieter ^d   Conter, Valentino ^g   Schrappe, Martin ^e   Biondi, Andrea ^a   Dworzak, Michael N ^b   Basso, Giuseppe ^c   more..

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Children's Cancer Research Institute and St Anna Children's Hospital   (Austria)

^c UNIVERSITY OF PADOVA   (Italy)

^d Section of Pathology   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY OF FLORENCE   (Italy)

^g OSPEDALI RIUNITI   (Italy)

Author keywords

Childhood ALL; Minimal residual disease; Prognostic value

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; DIAGNOSTIC TEST ACCURACY STUDY; EVENT FREE SURVIVAL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INFANT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PREDICTIVE VALUE; PRESCHOOL CHILD; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; COMPARATIVE STUDY; MORTALITY; REPRODUCIBILITY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FLOW CYTOMETRY; HUMANS; INFANT; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84867249480     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.060426     Document Type: Article

References (40)

1. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet. 1994;343(8891):196-200.
2. van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352(9142):1731-8.
3. Cavé H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer Childhood-Leukemia Cooperative Group. N Engl J Med. 1998;339(9):591-8.
4. Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk BI, Ribeiro RC, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002;100(1):52-8.
5. Dworzak MN, Fröschl G, Printz D, Mann G, Pötschger U, Mühlegger N, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99(6):1952-8.
6. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111(12):5477-85.
7. Knechtli CJ, Goulden NJ, Hancock JP, Grandage VL, Harris EL, Garland RJ, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood. 1998;92(11): 4072-9.
8. Bader P, Hancock J, Kreyenberg H, Goulden NJ, Niethammer D, Oakhill A, et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 2002; 16(9):1668-72.
9. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-14.
10. Eckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann B, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet. 2001;358(9289):1239-41.
11. Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol. 2003;121(6):823-38.
12. Szczepaski T, Orfão A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol. 2001;2(7):409-17.
13. Foroni L, Harrison CJ, Hoffbrand AV, Potter MN. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. Br J Haematol. 1999;105(1):7-24.
14. Pongers-Willemse MJ, Seriu T, Stolz F, D'Aniello E, Gameiro P, Pisa P, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13(1):110-8.
15. Campana D, Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2002;15(1):1-19.
16. van der Velden VH, Panzer-Grümayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A, et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia. 2007;21(4):706-13.
17. van der Velden VH, Cazzaniga G, Schrauder, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4):604-11.
18. Flohr T, Schrauder A, Cazzaniga G, Panzer- Grümayer R, van der Velden V, Fischer S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22(4):771-82.
19. Dworzak MN, Gaipa G, Ratei R, Veltroni M, Schumich A, Maglia O, et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. Cytometry B Clin Cytom. 2008;74(6):331-40.
20. Lúcio P, Parreira A, van den Beemd MW, van Lochem EG, van Wering ER, Baars E, et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor- B-ALL. Leukemia. 1999;13(3):419-27.
21. Dworzak MN, Fritsch G, Fleischer C, Printz D, Fröschl G, Buchinger P, et al. Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow. Leukemia. 1997;11(8):1266-73.
22. van Wering ER, van der Linden-Schrever BE, Szczepaski T, Willemse MJ, Baars EA, van Wijngaarde-Schmitz HM, et al. Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease. Br J Haematol. 2000;110(1): 139-46.
23. van Wering ER, Beishuizen A, Roeffen ET, van der Linden-Schrever BE, Verhoeven MA, Hählen K, et al. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. Leukemia. 1995;9(9):1523-33.
24. Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group. Cytometry B Clin Cytom. 2005;68(1):18-24.
25. Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G, et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia. 2005;19(1):49-56.
26. Neale GA, Coustan-Smith E, Pan Q, Chen X, Gruhn B, Stow P, et al. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 1999;13(8): 1221-6.
27. Neale GA, Coustan-Smith E, Stow P, Pan Q, Chen X, Pui CH, et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2004;18(5):934-8.
28. Malec M, van der Velden VH, Björklund E, Wijkhuijs JM, Söderhäll S, Mazur J, et al. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping. Leukemia. 2004;18(10):1630-6.
29. Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E, et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol. 2005;128(6):774-82.
30. Ryan J, Quinn F, Meunier A, Boublikova L, Crampe M, Tewari P, et al. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time points reveals high levels of concordance between molecular and immunophenotypic approaches. Br J Haematol. 2009; 144(1):107-15.
31. Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2009;27(31): 5168-74.
32. Basso G, Buldini B, De Zen L, Orfao A. New methodologic approaches for immunophenotyping acute leukemias. Haematologica. 2001;86(7):675-92.
33. Veltroni M, De Zen L, Sanzari MC, Maglia O, Dworzak MN, Ratei R, et al. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica. 2003;88(11):1245-52.
34. Porwit-MacDonald A, Björklund E, Lucio P, van Lochem EG, Mazur J, Parreira A, et al. BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia. 2000;14(5):816-25.
35. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 1999;38(4): 139-52.
36. Dworzak MN, Fröschl G, Printz D, Zen LD, Gaipa G, Ratei R, et al. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia. 2004;18(4):703-8.
37. Bland, J.M. & Altman, D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307-10.
38. Gaipa G, Basso G, Aliprandi S, Migliavacca M, Vallinoto C, Maglia O, et al. Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. Cytometry B Clin Cytom. 2008;74(3):150-5.
39. Panzer-Grümayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000;95(3):790-4.
40. Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFMALL 2000 study. Blood. 2011;118(8):2077-84.